Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy).  

Our platform is commercially validated by well over $7.6 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin. 

These partnerships have rapidly translated Synaffix technology into >20 ADCs currently in development by our partners, where 5 of these have already initiated Phase 1 clinical trials.

Through the platform, we can rapidly generate best-in-class ADCs for our partners from any antibody and our patent portfolio protects our proprietary processes and any resulting Products through at least 2039. 

Additionally, Synaffix technology is being deployed to address unmet medical need in several multi-billion-dollar, high growth market segments such as immune cell engagers and targeted gene therapy.

Synaffix BV was acquired by Lonza in May 2023.

Biotechnology

Synaffix BV

Peter van de Sande

Sven Zimmer

Peter Tjeerdsma

Sander Van Berkel

Harold Jansen

Anthony Deboer

The Business Development Team at Synaffix BV is responsible for identifying and securing new partnership opportunities, negotiating and managing licensing deals, and fostering relationships with key stakeholders across the biotech and pharmaceutical industries. This team drives the commercialization of Synaffix’s proprietary ADC technology platform by developing strategic collaborations that expand the company’s reach and market presence. They are instrumental in translating Synaffix’s innovations into clinical-stage developments, contributing to the overall growth and success of the company.

Business Development Team

About

Team members